Table 1.

Patients characteristics, FAB-classification, molecular and cytogenetics of primary AML samples.

Sample	FAB	WHO	Age	% Blasts in PB	Molecular genetics	Cytogenetics
AML007	M2	AM L with maturation	55–60	92	FLT3-ITD	46, XY
AML011	M5	Acute monoblastic and monocytic leukemia	85–90	95	nd	nd
AML012	M4	AML with mutated NPM1	55–60	86	FLT3-ITD NPM1 mut	46, XY
AML014	nd	AML, NOS	70–75	95	nd	nd
AML101	M4	Acute myelomonocytic leukemia	30–35	90	FLT3-ITD	46, XY
AML109	nd	AML with myelodysplasia-related changes	80–85	86	nd	46, XXder(7), t(7;11), dupl(11)
AML110	M5	AML with mutated NPM1	70–75	90	NPM1 mut	46, XY
AML111	M2	AML with biallelic mutation of CEBPA	45–50	96	Biallelic CEBPA mut	46, XY
AML128	M4	Acute myelomonocytic leukemia	75–80	93	nd	nd
AML135	M2	AML with mutated NPM1	45–50	70	FLT3-ITD NPM1 mut	nd
AML144	nd	AML with mutated NPM1	85–90	80	FLT3-ITD NPM1 mut	nd
AML147	nd	AML, NOS	70–75	86	FLT3-ITD	46Xdel(X), del(18)
AML151	MO	AML with mutated NPM1	65–70	90	FLT3-ITD NPM1 mut	46, XX
AML172	M1	AML without maturation	65–70	70	FLT3-ITD	46, XY

CEBPA, CCAAT/enhancer-binding protein alpha; FAB, French-American-British Cooperative Group; NOS, not otherwise specified; NPM1, nucleophosmin 1; FLT3, FMS-like tyrosine kinase-3; -ITD: internal tandem duplication; nd, not determined; WHO, World Health Organization.